New eye drug GB10 enters early human testing for wet AMD
Disease control
Not yet recruiting
This early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC